(Q33834118)

29 July 2017

1 reference

title

HIV protease: enzyme function and drug resistance (English)

1 reference

29 July 2017

Gulnik S

1

1 reference

PubMed ID

10668400

29 July 2017

Erickson JW

series ordinal

2

1 reference

PubMed ID

10668400

29 July 2017

Xie D

series ordinal

3

1 reference

29 July 2017

1 January 2000

1 reference

29 July 2017

Vitamins and Hormones

1 reference

29 July 2017

58

1 reference

29 July 2017

213-256

1 reference

Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Molecular recognition of cyclic urea HIV-1 protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Use of experimental models for the study of collagen degradation by macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Resistance to human immunodeficiency virus type 1 protease inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Flap opening in HIV-1 protease simulated by 'activated' molecular dynamics.

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Dissociation and association of the HIV-1 protease dimer subunits: equilibria and rates.

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

The HIV-1 protease as a therapeutic target for AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

HIV-1 protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

The not-so-great escape

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Structural mechanisms of HIV drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Determination of the relative binding free energies of peptide inhibitors to the HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

HIV-protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Two-step binding mechanism for HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Use of protein unfolding studies to determine the conformational and dimeric stabilities of HIV-1 and SIV proteases

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Different requirements for productive interaction between the active site of HIV-1 proteinase and substrates containing -hydrophobic*hydrophobic- or -aromatic*pro- cleavage sites

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Molecular characterization of gag proteins from simian immunodeficiency virus (SIVMne).

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Human immunodeficiency virus protease ligand specificity conferred by residues outside of the active site cavity

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Large scale purification and refolding of HIV-1 protease from Escherichia coli inclusion bodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Human immunodeficiency virus-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Inhibition of retroviral protease activity by an aspartyl proteinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir.

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

New series of potent, orally bioavailable, non-peptidic cyclic sulfones as HIV-1 protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency.

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Sub-site preferences of the aspartic proteinase from the human immunodeficiency virus, HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

The HIV protease and therapies for AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

A cellular anti-apoptosis protein is cleaved by the HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays.

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

HTLV-III gag protein is processed in yeast cells by the virus pol-protease

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Stabilization of HIV proteinase dimer by bound substrate.

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Sensing the heat: the application of isothermal titration calorimetry to thermodynamic studies of biomolecular interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

X-ray analysis of HIV-1 proteinase at 2.7 A resolution confirms structural homology among retroviral enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Molecular basis of resistance to HIV-1 protease inhibition: a plausible hypothesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

The HIV-1 protease as enzyme and substrate: mutagenesis of autolysis sites and generation of a stable mutant with retained kinetic properties.

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Recent developments in HIV protease inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Current knowledge and future prospects for the use of HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Determination of kinetic rate constants for the binding of inhibitors to HIV-1 protease and for the association and dissociation of active homodimer

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

A structural model for the retroviral proteases.

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Hydrolysis of synthetic chromogenic substrates by HIV-1 and HIV-2 proteinases

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Substrate-dependent mechanisms in the catalysis of human immunodeficiency virus protease

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Triterpenes as potential dimerization inhibitors of HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Development of drug resistance to HIV-1 protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Processing of the precursor of NF-kappa B by the HIV-1 protease during acute infection

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: theory and practice

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Rational design of peptide-based HIV proteinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Domain flexibility in retroviral proteases: structural implications for drug resistant mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

On the size of the active site in proteases. I. Papain

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

The inhibition of human immunodeficiency virus proteases by 'interface peptides'.

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Inhibition and catalytic mechanism of HIV-1 aspartic protease

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Ionization states of the catalytic residues in HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Characterization and autoprocessing of precursor and mature forms of human immunodeficiency virus type 1 (HIV 1) protease purified from Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Rate-determining steps in HIV-1 protease catalysis. The hydrolysis of the most specific substrate

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

A kinetic model for comparing proteolytic processing activity and inhibitor resistance potential of mutant HIV-1 proteases

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Structural evidence for gene duplication in the evolution of the acid proteases

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

The structural stability of the HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Retroviral protease-like sequence in the yeast transposon Ty 1

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Calcium-free calmodulin is a substrate of proteases from human immunodeficiency viruses 1 and 2

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Kinetic and modeling studies of S3-S3' subsites of HIV proteinases

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Solution NMR evidence that the HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272.

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Targeting HIV-1 protease: a test of drug-design methodologies

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Escape mutants of HIV-1 proteinase: enzymic efficiency and susceptibility to inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Structure-based inhibitors of HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Inhibitors of HIV-1 protease: a major success of structure-assisted drug design

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Thermodynamics and proton uptake for pepstatin binding to retroviral and eukaryotic aspartic proteases

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Drug resistance mutations can effect dimer stability of HIV-1 protease at neutral pH.

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

pol gene diversity of five human immunodeficiency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D.

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles.

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

The activity of the protease of human immunodeficiency virus type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency.

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0083-6729%2800%2958026-1

7 January 2021

10.1016/S0083-6729(00)58026-1

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10668400